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Clinical PerspectiveWhat Is New?Women and black patients have longer ST‐segment--elevation myocardial infarction (STEMI) treatment times compared with men and white patients.Establishment of regional systems of STEMI care has been shown to improve overall STEMI treatment times, but its impact on care disparities by sex and race is less clear.What Are the Clinical Implications?Despite implementing regional systems of STEMI care across health systems in the United States, disparities in STEMI care persist among women and black patients.This study highlights the need to develop regional care efforts to implement additional processes to overcome barriers to care for women and black patients.

Introduction {#jah32576-sec-0008}
============

The cornerstone of acute ST‐segment--elevation myocardial infarction (STEMI) treatment is prompt coronary artery reperfusion to reduce morbidity and mortality. National guidelines call for primary percutaneous coronary intervention (PCI) within 90 minutes of paramedic arrival for patients who call 9‐1‐1 and are transferred directly to a hospital offering PCI (PCI‐capable) and within 120 minutes of first medical contact (FMC) for patients requiring interhospital transfer.[1](#jah32576-bib-0001){ref-type="ref"} Nevertheless, up to 50% of patients presenting with STEMI fail to meet national guideline goals for reperfusion therapy.[2](#jah32576-bib-0002){ref-type="ref"}, [3](#jah32576-bib-0003){ref-type="ref"}, [4](#jah32576-bib-0004){ref-type="ref"}, [5](#jah32576-bib-0005){ref-type="ref"} Furthermore, disparities in both the use and the timing of reperfusion therapy may exist in vulnerable patient populations, including women and minorities, particularly black patients.[6](#jah32576-bib-0006){ref-type="ref"}, [7](#jah32576-bib-0007){ref-type="ref"}, [8](#jah32576-bib-0008){ref-type="ref"}, [9](#jah32576-bib-0009){ref-type="ref"}, [10](#jah32576-bib-0010){ref-type="ref"}, [11](#jah32576-bib-0011){ref-type="ref"} However, little contemporary evidence exists to describe care gaps among such disparate groups, particularly on a national level.

The Regional Systems of Care Demonstration Project American Heart Association Mission: Lifeline STEMI Systems Accelerator program represented the largest effort in the United States to organize regional STEMI care. It significantly increased the proportion of patients treated within guideline goals and significantly reduced reperfusion times among hospitals implementing care processes compared with those that did not.[12](#jah32576-bib-0012){ref-type="ref"}, [13](#jah32576-bib-0013){ref-type="ref"} Recent efforts to improve STEMI reperfusion times have identified systemic barriers to care resulting from a highly fragmented healthcare system as a primary impediment to the delivery of rapid reperfusion.[12](#jah32576-bib-0012){ref-type="ref"}, [14](#jah32576-bib-0014){ref-type="ref"}, [15](#jah32576-bib-0015){ref-type="ref"}, [16](#jah32576-bib-0016){ref-type="ref"} To address system‐related delays, interventions were conducted with the goal of identifying regional gaps, barriers, and inefficiencies in STEMI care and to implement proven recommendations and protocols to improve quality and consistency of care. Key study interventions included organizing and training regional leadership, identifying barriers to care unique to each region, establishing common protocols for the diagnosis and treatment of patients with STEMI presenting to emergency medical services (EMS) personnel or hospitals lacking PCI facilities, conducting ongoing measurement of and feedback on performance in hospitals, and having regular reviews of performance with representatives of hospitals and EMS agencies.

Despite the success of these programs, little is known about the specific impact of rapidly implementing multiple STEMI regional networks on care disparities, including among female and black patients. The objective of this study was to determine the impact of implementing regional systems of STEMI care on the proportion of patients treated within reperfusion time guideline goals for female versus male and black versus white patients and to determine whether the intervention narrowed disparities between these groups.

Methods {#jah32576-sec-0009}
=======

Study Design and Population {#jah32576-sec-0010}
---------------------------

This study analyzed data collected over 7 calendar quarters from July 1, 2012 (2012 quarter 3), through March 31, 2014 (2014 quarter 1), as part of the STEMI Systems Accelerator project. The design and methods for this study have been published.[17](#jah32576-bib-0017){ref-type="ref"} In brief, the STEMI Systems Accelerator project was a nationwide effort to organize and implement STEMI reperfusion therapy in 16 regions across the United States and included 484 hospitals and 1253 EMS agencies. The enrollment criteria for each region included the following: (1) 70% of PCI‐capable hospitals in the region were participating in the National Cardiovascular Data Registry\'s ACTION Registry--Get With The Guidelines (AR‐G) program; (2) there was defined organization of regional leadership; (3) common protocols were established for the diagnosis and treatment of patients with STEMI presenting to EMS personnel or hospitals lacking PCI facilities; (4) there was agreement to enter patients into the AR‐G for 6 consecutive quarters; and (5) regional leadership participated in a 2‐day national training session directed by study faculty reviewing current evidence, guidelines, and approaches to regional STEMI care. The following 16 of 21 regions that applied for participation in the project met enrollment criteria by the baseline data collection quarter and were included: Atlanta, GA; Columbus, OH; Denver, CO; Hartford, CT; Houston, TX; Kern County, CA; Louisville, KY; New York, NY; northern New Jersey; Oklahoma City, OK; Philadelphia, PA; Pittsburgh, PA; St. Louis, MO; San Antonio, TX; Tampa, FL; and Wilkes‐Barre/Scranton, PA.

Regional interventions were based on Mission: Lifeline established approaches and drew on specific resources that effectively augmented regional organization in prior experience (Data [S1](#jah32576-sup-0001){ref-type="supplementary-material"}).[18](#jah32576-bib-0018){ref-type="ref"} Each region established common protocols, including common criteria for establishing the diagnosis of STEMI, activating a catheterization laboratory with a single phone or radio call, treating the patient with simple initial regimens, and transporting the patient by preidentified mechanisms. Common protocols were implemented, and ongoing performance measurement and feedback were conducted and reflected in quarterly hospital STEMI treatment reports.

Each region identified a quarter (quarters 3 or 4 of 2012 or quarter 1 of 2013) as the baseline quarter (Q1) from which to assess subsequent temporal trends in outcomes. All patients with ongoing ischemic symptoms lasting for \>10 minutes but \<12 hours, with ECG‐diagnosed ST‐segment elevation, and treated with primary PCI were included. Patients were included in the direct presenter group if they presented to a PCI‐capable hospital (capable of performing PCI 24/7) either by EMS transport or self‐transport. Patients were included in the transfer group if they presented to a hospital without PCI capabilities and were subsequently transferred to a PCI‐capable hospital. Analysis was performed on the overall population represented by all 16 regions.

Study Outcome {#jah32576-sec-0011}
-------------

The primary outcome of this study was the percentage of patients meeting guideline goals for FMC‐to‐device time. The outcome was analyzed by sex and race in each of the 7 quarters.

Statistical Analyses {#jah32576-sec-0012}
--------------------

Analyses were conducted to determine the change in the percentage of patients (female versus male and black versus white) meeting guideline goals for 6 quarters (after the baseline quarter). Descriptive statistics for continuous variables were presented as medians (25th and 75th percentiles). The Cochran--Armitage test for trend was used to assess changes in rates over time. Categorical variables are presented as frequencies with percentages. Baseline characteristics were compared using the Wilcoxon rank sum test for continuous variables and the Pearson χ^2^ or Fisher exact test, as appropriate, for categorical variables. In‐hospital mortality was analyzed using the logistic regression model with generalized estimating equations to account for clustering of patients within each hospital. Mixed‐effects models were used to estimate the effect of sex and race on the dependent variable of FMC‐to‐device time and the interaction between sex or race and intervention.

All statistical tests were conducted at the nominal 0.05 significance level. Statistical analyses were performed with SAS version 9.2 or higher (SAS Institute). The project was reviewed by the Duke University institutional review board and classified as exempt.

Results {#jah32576-sec-0013}
=======

Patient Characteristics and Presentation {#jah32576-sec-0014}
----------------------------------------

A total of 23 809 patients presented with acute STEMI from July 2012 through March 2014. The population was 70.7% male, 29.3% female, 82.3% white, and 10.7% black. Overall, 77% of patients were in the direct presenter group and 23% were in the transfer group. Of the 23 809 patients, 20 797 were treated by primary PCI within 12 hours of symptom onset and were included in the primary outcome analysis. Patient demographics, medical history, presenting clinical characteristics, and in‐hospital complications are shown in Tables [1](#jah32576-tbl-0001){ref-type="table"} and [2](#jah32576-tbl-0002){ref-type="table"}.

###### 

Patient Characteristics by Sex

                                  Direct Presenter   Transfers                                           
  ------------------------------- ------------------ ------------- --------- ------------- ------------- ----------
  Demographics                    n=12 813           n=5454                  n=4021        n=1521        
  Age, y                                                           \<0.001                               \<0.001
  Median                          59                 66                      58            64            
  Q1--Q3                          51--67             56--78                  51--66        54--75        
  Race, n (%)                                                      0.114                                 0.651
  White                           10 485 (81.8)      4500 (82.5)             3349 (83.3)   1266 (83.2)   
  Black                           1428 (11.1)        617 (11.3)              362 (9.0)     146 (9.6)     
  Other                           900 (7.0)          337 (6.2)               310 (7.7)     109 (7.2)     
  Insurance, n (%)                                                                                       
  Private/HMO                     7194 (56.1)        2806 (51.4)   \<0.001   2254 (56.1)   855 (56.2)    0.013
  Medicare                        3860 (30.1)        2593 (47.5)   \<0.001   1223 (30.4)   690 (45.4)    \<0.001
  Medicaid                        1030 (8.0)         729 (13.4)    \<0.001   339 (8.4)     197 (13.0)    \<0.001
  None                            2328 (18.2)        650 (11.9)    \<0.001   703 (17.5)    188 (12.4)    \<0.001
  Other                           2362 (18.4)        1358 (24.9)   \<0.001   755 (18.8)    303 (19.9)    0.333
  Medical history, n (%)                                                                                 
  Hypertension                    8139 (63.5)        3924 (71.9)   \<0.001   2507 (62.3)   1047 (68.8)   \<0.001
  Current/recent smoker           5262 (41.1)        1998 (36.6)   \<0.001   1794 (44.6)   656 (43.1)    0.330
  Dyslipidemia                    4483 (35.0)        1973 (36.2)   0.114     1334 (33.2)   497 (32.7)    0.200
  Chronic lung disease            605 (4.7)          470 (8.6)     \<0.001   234 (5.8)     127 (8.3)     \<0.001
  Diabetes mellitus               3170 (24.7)        1746 (32.0)   \<0.001   921 (22.9)    491 (32.3)    \<0.001
  Prior MI                        1661 (13.0)        574 (10.5)    \<0.001   438 (10.9)    142 (9.3)     0.303
  Prior heart failure             370 (2.9)          261 (4.8)     \<0.001   103 (2.6)     54 (3.6)      0.017
  Prior PCI                       1833 (14.3)        612 (11.2)    \<0.001   475 (11.8)    143 (9.4)     0.057
  Prior CABG                      515 (4.0)          170 (3.1)     0.003     175 (4.4)     35 (2.3)      0.001
  Presentation                                                                                           
  Arrival mode                                                                                           
  EMS transport                   8002 (62.5)        3763 (69.0)   \<0.001   NA            NA            
  Self‐transport                  4811 (37.5)        1691 (31.0)   \<0.001   NA            NA            
  Door‐in to door‐out time, min                                                                          \<0.0001
  Median                          NA                 NA                      60            65            
  Q1--Q3                          NA                 NA                      41--97        45--112       
  Symptom onset to FMC, min                                        \<0.001                               \<0.001
  Median                          60                 70                      86            100           
  Q1--Q3                          29.0--152.0        30.0--184.0             45.0--188.0   50.5--250.0   
  ED time (min), n (%)                                             \<0.001                               0.694
  ≤20                             2385 (18.6)        779 (14.3)              410 (10.2)    160 (10.5)    
  \>20 to ≤30                     2073 (16.2)        766 (14.0)              184 (4.6)     72 (4.7)      
  \>30 to ≤45                     2904 (22.7)        1145 (21.0)             614 (15.3)    236 (15.5)    
  \>45                            4376 (34.2)        2012 (36.9)             536 (13.3)    184 (12.1)    
  Shock, n (%)                    1026 (8.0)         502 (9.2)     0.008     307 (7.6)     158 (10.4)    \<0.001
  Heart failure, n (%)            776 (6.1)          481 (8.8)     \<0.001   278 (6.9)     139 (9.1)     0.005
  Reperfusion candidate, n (%)    12 330 (96.2)      5098 (93.5)   \<0.001   3811 (94.8)   1423 (93.6)   0.075
  Heart rate                                                       0.002                                 0.002
  Median                          79                 80                      78            80            
  Q1--Q3                          66--93             66--96                  65--93        68--96        
  Systolic BP, mm Hg                                               \<0.001                               0.087
  Median                          140                138                     143           142           
  Q1--Q3                          119--161           114--160                122--163      120--161      
  Complications, n (%)                                                                                   
  In‐hospital death               671 (5.2)          465 (8.5)     \<0.001   188 (4.7)     118 (7.8)     \<0.001
  Stroke                          78 (0.6)           57 (1.0)      0.002     35 (0.9)      16 (1.1)      0.530
  Cardiogenic shock               948 (7.4)          502 (9.2)     0.625     282 (7.0)     139 (9.1)     0.008
  Congestive heart failure        714 (5.6)          429 (7.9)     \<0.001   232 (5.8)     113 (7.4)     0.023
  Major bleeding                  451 (3.5)          336 (6.2)     \<0.001   133 (3.3)     100 (6.6)     \<0.001

BP indicates blood pressure; CABG, coronary artery bypass grafting; ED, emergency department; EMS, emergency medical services; FMC, first medical contact; HMO, health maintenance organization; MI, myocardial infarction; NA, not assessed; PCI, percutaneous coronary intervention; Q, quarter.

###### 

Patient Characteristics by Race

                                 Direct Presenter   Transfers                                           
  ------------------------------ ------------------ ------------- --------- ------------- ------------- ---------
  Demographics                   n=14 985           n=2045                  n=4615        n=508         
  Age, y                                                          \<0.001                               0.776
  Median                         61                 60                      60            60            
  Q1--Q3                         53--71             52--70                  52--69        51--69        
  Sex, n (%)                                                      0.896                                 0.531
  Male                           10 485 (70.0)      1428 (69.8)             3349 (72.6)   362 (71.3)    
  Female                         4500 (30.0)        617 (30.2)              1266 (27.4)   146 (28.7)    
  Insurance, n (%)                                                                                      
  Private/HMO                    8434 (56.3)        968 (47.3)    \<0.001   2625 (56.9)   258 (50.8)    0.591
  Medicare                       5337 (35.6)        718 (35.1)    \<0.001   1609 (34.9)   171 (33.7)    \<0.001
  Medicaid                       1414 (9.4)         224 (11.0)    \<0.001   448 (9.7)     45 (8.9)      0.740
  None                           2307 (15.4)        414 (20.2)    \<0.001   728 (15.8)    98 (19.3)     0.041
  Other                          2970 (19.8)        477 (23.3)    \<0.001   857 (18.6)    112 (22.0)    0.058
  Medical history, n (%)                                                                                
  Hypertension                   9766 (65.2)        1452 (71.0)   \<0.001   2907 (63.0)   347 (68.3)    0.019
  Current/recent smoker          5997 (40.0)        826 (40.4)    0.750     2046 (44.3)   201 (39.6)    0.040
  Dyslipidemia                   5211 (34.8)        721 (35.3)    0.024     1540 (33.4)   154 (30.3)    0.005
  Chronic lung disease           916 (6.1)          96 (4.7)      0.035     323 (7.0)     17 (3.3)      0.043
  Diabetes mellitus              3913 (26.1)        653 (31.9)    \<0.001   1137 (24.6)   150 (29.5)    0.017
  Prior MI                       1800 (12.0)        261 (12.8)    0.069     494 (10.7)    40 (7.9)      0.777
  Prior heart failure            488 (3.3)          85 (4.2)      0.010     131 (2.8)     11 (2.2)      0.983
  Prior PCI                      1991 (13.3)        265 (13.0)    0.687     523 (11.3)    47 (9.3)      0.656
  Prior CABG                     580 (3.9)          52 (2.5)      0.008     182 (3.9)     16 (3.1)      0.878
  Presentation                                                                                          
  Arrival mode                                                                                          
  EMS transport                  9510 (63.3)        1456 (71.2)   \<0.001   NA            NA            
  Self‐transport                 5475 (36.7)        589 (28.8)    0.869     NA            NA            
  Door‐in--door‐out time, min                                                                           \<0.001
  Median                         NA                 NA                      60            73            
  Q1--Q3                         NA                 NA                      41--97        43--129       
  Symptom onset--FMC, min                                         0.983                                 0.036
  Median                         63                 61                      88            106           
  Q1--Q3                         30.0--161.0        30.0--170.0             47.0--196.0   51.0--254.0   
  ED time (min), n (%)                                            0.353                                 \<0.001
  ≤20                            2594 (17.3)        323 (15.8)              391 (8.5)     62 (12.2)     
  \>20--≤30                      2307 (15.4)        323 (15.8)              186 (4.0)     70 (13.8)     
  \>30--≤45                      3362 (22.4)        430 (21.0)              584 (12.7)    116 (22.8)    
  \>45                           5268 (35.2)        724 (35.4)              553 (12.0)    134 (26.4)    
  Shock, n (%)                   1228 (8.2)         190 (9.3)     0.094     391 (8.5)     51 (10.0)     0.237
  Heart failure, n (%)           948 (6.3)          163 (8.0)     0.005     345 (7.5)     37 (7.3)      0.878
  Reperfusion candidate, n (%)   14 321 (95.6)      1913 (93.5)   0.006     4363 (94.5)   467 (91.9)    0.019
  Heart rate                                                      0.002                                 0.027
  Median                         80                 80                      79            80            
  Q1--Q3                         66--94             67--96                  65--93        68--95        
  Systolic BP, mm Hg                                              0.990                                 0.749
  Median                         140                140                     143           140           
  Q1--Q3                         118--161           118--160                122--163      121--164      
  Complications, n (%)                                                                                  
  In‐hospital death              905 (6.0)          138 (6.7)     0.210     247 (5.4)     32 (6.3)      0.372
  Stroke                         102 (0.7)          23 (1.1)      0.028     41 (0.9)      5 (1.0)       0.803
  Cardiogenic shock              1152 (7.7)         186 (9.1)     0.027     330 (7.2)     47 (9.3)      0.086
  Congestive heart failure       901 (6.0)          152 (7.4)     0.013     267 (5.8)     32 (6.3)      0.644
  Major bleeding                 632 (4.2)          103 (5.0)     0.088     194 (4.2)     15 (3.0)      0.175

BP indicates blood pressure; CABG, coronary artery bypass grafting; ED, emergency department; EMS, emergency medical services; FMC, first medical contact; HMO, health maintenance organization; MI, myocardial infarction; NA, not assessed; PCI, percutaneous coronary intervention; Q, quarter.

Women were significantly older and had significantly more comorbidities, including hypertension, chronic lung disease, diabetes mellitus, and prior heart failure, compared with men. Women were also more likely to have Medicare or Medicaid insurance. Women had a longer delay between symptom onset and FMC and were more likely to arrive by EMS transport rather than self‐transport. Women who were transferred had a significantly longer door‐in to door‐out time compared with men. Women also had significantly more in‐hospital complications, including in‐hospital death, congestive heart failure, and major bleeding.

Black patients had significantly higher rates of diabetes mellitus and hypertension and were more likely to be uninsured compared with white patients. Among those transferred, black patients had significantly longer door‐in to door‐out times. Among direct presenters, black patients had higher rates of in‐hospital complications including cardiogenic shock and congestive heart failure, whereas complication rates were similar for black and white patients in the transfer group. In‐hospital mortality was similar for black and white patients.

Direct Presenter Group {#jah32576-sec-0015}
----------------------

In each quarter, a higher proportion of men were treated within guideline goals compared with women. The proportion of women presenting directly to a PCI‐capable hospital that met guideline goals for FMC‐to‐device time (\<90 minutes) did not change (53.5% in Q1 to 54.2% in Q7, *P*=0.26). However, the proportion of directly presenting men treated within guideline goals increased significantly from 58.7% in Q1 to 62.1% in Q7 (*P*=0.01) (Figure [1](#jah32576-fig-0001){ref-type="fig"}). The sex and intervention interaction terms were not significant.

![Percentage of patients meeting guideline goals for FMC‐to‐device time by quarter and sex. Patients arrived directly at hospitals capable of performing percutaneous coronary intervention (A) or were transferred (B). FMC indicates first medical contact.](JAH3-6-e007122-g001){#jah32576-fig-0001}

In each quarter, a higher proportion of white patients were treated within guideline goals compared with black patients. The proportion of black patients in the direct presenter group meeting guideline goals did not change (54.0% in Q1 to 56.0% in Q7, *P*=0.43). However, the proportion of white patients in the direct presenter group meeting guideline goals increased modestly but significantly from 57.7% in Q1 to 59.9% in Q7 (*P*=0.02) (Figure [2](#jah32576-fig-0002){ref-type="fig"}). The race and intervention interaction terms were not significant.

![Percentage of patients meeting guideline goals for FMC‐to‐device time by quarter and race. Patients arrived directly at hospitals capable of performing percutaneous coronary intervention (A) or were transferred (B). FMC indicates first medical contact.](JAH3-6-e007122-g002){#jah32576-fig-0002}

Transfer Group {#jah32576-sec-0016}
--------------

Among transfers in all regions over 7 calendar quarters, the proportion of women who were transferred to a PCI‐capable hospital meeting guideline goals for FMC‐to‐device time (\<120 minutes) did not change over the course of the intervention (42.8% in Q1 to 36.5% in Q7, *P*=0.53). The proportion of transferred male patients meeting guideline goals significantly increased from 43.3% in Q1 to 50.7% in Q7 (*P*\<0.01) (Figure [1](#jah32576-fig-0001){ref-type="fig"}). The sex and intervention interaction terms were not significant.

The proportion of black patients in the transfer group treated within guideline goals decreased, although this was not statistically significant (42.9% in Q1 to 32.3% in Q7, *P*=0.54). The proportion of white patients in the transfer group meeting guideline goals significantly increased from 43.9% in Q1 to 48.8% in Q7 (*P*\<0.01) (Figure [2](#jah32576-fig-0002){ref-type="fig"}). In each quarter, a higher proportion of white patients were reperfused within guideline goals compared with black patients. The race and intervention interactions term were not significant.

Discussion {#jah32576-sec-0017}
==========

Establishment of regional systems of STEMI care has been shown to improve STEMI treatment times and is a class I recommendation in the American College of Cardiology Foundation and American Heart Association STEMI management guidelines.[1](#jah32576-bib-0001){ref-type="ref"}, [19](#jah32576-bib-0019){ref-type="ref"} In this study, implementing systems of STEMI care across multiple regions was associated with a significant increase in the proportion of male and white patients meeting guideline goals for FMC‐to‐device times among both direct presenters and transfers that was not evident for female or black patients, highlighting important contemporary care gaps that remain in the United States despite regional efforts.

Disparities in the management of STEMI by sex have been documented previously.[6](#jah32576-bib-0006){ref-type="ref"}, [7](#jah32576-bib-0007){ref-type="ref"}, [8](#jah32576-bib-0008){ref-type="ref"}, [9](#jah32576-bib-0009){ref-type="ref"}, [11](#jah32576-bib-0011){ref-type="ref"} A study of 2.5 million patients in the National Registry of Myocardial Infarction database demonstrated that women were significantly less likely to receive reperfusion therapy compared with men.[11](#jah32576-bib-0011){ref-type="ref"} Although the use of primary PCI for STEMI remained imbalanced in the current study, differences between men and women have significantly narrowed, particularly following intervention (Q1: 91.1% in men versus 84% in women, *P*\<0.01; Q6 and Q7: 91.5% in men versus 87.1% in women, *P*\<0.01). Furthermore, prior studies have shown that women who do receive reperfusion therapy have longer overall ischemic times and door‐to‐balloon times compared with men.[6](#jah32576-bib-0006){ref-type="ref"}, [7](#jah32576-bib-0007){ref-type="ref"}, [9](#jah32576-bib-0009){ref-type="ref"} This study extends these prior findings by consistently demonstrating that a higher proportion of men were reperfused within guideline goals compared with women despite a national effort to organize STEMI care across multiple STEMI networks.

Despite the success of programs organizing regional systems of STEMI care, the impact of these programs on disparities in reperfusion therapy by sex is not well characterized. To our knowledge, the only other study to examine this is the RACE (Reperfusion of Acute Myocardial Infarction in North Carolina Emergency Departments) study, a statewide systems of STEMI care project conducted in North Carolina, which demonstrated that women had significant improvement in door‐to‐device times although not to a greater extent than men.[6](#jah32576-bib-0006){ref-type="ref"} The considerably larger and heterogeneous population of the STEMI Systems Accelerator project, which was implemented across multiple systems of care in the United States, allowed for more widespread characterization of the impact of organizing STEMI care in vulnerable patient populations. In contrast to the results of the RACE study, the intervention in this study benefited men but not women. The difference in findings may be explained by the use of the more contemporary FMC‐to‐device time (incorporating prehospital system delays) rather than door‐to‐device time or by heterogeneity in both patient population and regional differences over time.

Similar to women, black patients are also less likely to receive reperfusion therapy compared with white patients, and those who are treated by primary PCI have longer reperfusion times.[10](#jah32576-bib-0010){ref-type="ref"}, [11](#jah32576-bib-0011){ref-type="ref"}, [20](#jah32576-bib-0020){ref-type="ref"}, [21](#jah32576-bib-0021){ref-type="ref"} Differences between black and white patients in the use of primary PCI in this study was redemonstrated in the preintervention group (89.3% in white versus 84.9% in black patients in Q1, *P*=0.01) but were no longer present following intervention (90.6% in white versus 88.2% in black patients in Q6 and Q7, *P*=0.14). Consistent with prior findings, this study also showed that black patients had longer reperfusion times compared with white patients.[10](#jah32576-bib-0010){ref-type="ref"}, [21](#jah32576-bib-0021){ref-type="ref"}

Although implementing regional systems of STEMI care improves reperfusion times and the proportion of patients reperfused within guideline goals, this study demonstrates that sex and race disparities in STEMI care persist despite intervention. Consequently, the intervention did not eliminate barriers to care among female and black patients. This study highlights future opportunities to further improve the impact of implementing regional systems of STEMI care by incorporating additional care processes that address treatment barriers unique to female and black patients. Reasons for sex‐ and race‐related disparities in STEMI care have been described previously.

Women have been shown to have longer reperfusion times compared with men for numerous reasons, including atypical symptoms and lack of chest discomfort, ECG with lower magnitude of ST‐segment elevation, greater likelihood of a missed prehospital diagnosis of STEMI, longer delay between ECG acquisition and activation of the catheterization team, higher incidence of presentation to a non‐PCI hospital, and higher risk of interhospital transfer resulting in delay of transfer.[8](#jah32576-bib-0008){ref-type="ref"}, [9](#jah32576-bib-0009){ref-type="ref"}, [22](#jah32576-bib-0022){ref-type="ref"}, [23](#jah32576-bib-0023){ref-type="ref"}, [24](#jah32576-bib-0024){ref-type="ref"}, [25](#jah32576-bib-0025){ref-type="ref"}, [26](#jah32576-bib-0026){ref-type="ref"} Delay in seeking medical care is also more frequent among women for several reasons, including less knowledge about symptoms of STEMI, advanced age, greater likelihood to contact their physician initially, and greater likelihood of living alone or being widowed.[27](#jah32576-bib-0027){ref-type="ref"} In this study, it is plausible that symptom presentation among women contributed to a longer delay in obtaining an ECG and confounded the diagnosis, which may be reflected in longer emergency department dwell times. In addition, a longer delay between symptom onset and FMC as well as older age and more comorbidities may explain the sicker initial presentation of women, with higher rates of cardiogenic shock and heart failure on presentation. Finally, women had significantly longer door‐in to door‐out times. The current intervention did not include education to specifically address atypical presentation in certain populations, including women and older adults. Additional education, particularly of EMS agencies, on the presentation in women and training to obtain an ECG even for atypical symptoms can allow for earlier diagnosis. In addition, providers should be educated to activate the catheterization team for a diagnostic ECG despite atypical symptoms. Finally, further analysis to understand why women have longer transfer times is necessary.

Race‐related disparities have been attributed predominantly to differences in the care delivered at hospitals that treat a higher proportion of minorities as well as income and type of insurance.[10](#jah32576-bib-0010){ref-type="ref"}, [21](#jah32576-bib-0021){ref-type="ref"}, [28](#jah32576-bib-0028){ref-type="ref"} In this study, black patients were more likely to be uninsured, and this may have contributed to differential care compared with white patients. Future endeavors should compare outcomes of hospitals that treat a higher proportion of black patients with other hospitals within the region to examine whether there are differences in care. Although common protocols should mitigate differences in care regardless of race, hospitals treating more black patients may face additional barriers that hinder the ability to execute these protocols. Hospitals vary substantially not only in overall door‐to‐balloon times but also in key hospital‐level subintervals, including door‐to‐ECG, ECG‐to‐lab, and lab‐to‐balloon times.[29](#jah32576-bib-0029){ref-type="ref"} Comparing these subintervals among hospitals treating minorities may help to more precisely identify areas in need of improvement. Furthermore, EMS agencies are funded on a local basis, and those servicing lower socioeconomic and underserved areas lack adequate resources, personnel, or training to successfully implement desired interventions, thus leading to delays in care.[30](#jah32576-bib-0030){ref-type="ref"} Ensuring adequate funding will be important to establish uniform application. In addition, this study showed that the greatest disparity in reperfusion times was among black patients in the transfer group: Only 32.3% of black patients met guideline goals compared with 48.8% of white patients. Furthermore, the door‐in to door‐out time was 13 minutes longer for black patients (*P*\<0.001). This identifies race‐related differences in interhospital transfers as a key area in need of further research and improvement. Finally, quarterly performance reports provided to each hospital could include outcomes by sex and race to provide feedback on the impact of implementing sex‐ and race‐specific care processes.

To our knowledge, this is the only multiregion study to determine the impact of implementing regional systems of STEMI care on female and black patients. Although effectuating care processes improves reperfusion times of an overall population, this study demonstrates a differential impact of the intervention based on sex and race. The current study showed a significant increase in the proportion of male and white patients treated within guideline goals that was not evident for female or black patients. This highlights the persistent disparity in STEMI care among female and black patients and the importance of ongoing regional care efforts to implement additional processes to target and eliminate barriers to care delaying reperfusion times in female and black patients.

Limitations {#jah32576-sec-0018}
-----------

This study has some limitations. Because of the observational nature of measurements, the relationships between the implementation of the STEMI Systems Accelerator project and treatment times and outcomes are subject to confounding, including cointervention. Quality‐improvement efforts by participating hospitals and EMS agencies may have contributed to the outcomes. In addition, the willingness of enrolled hospitals to participate in the AR‐G program may indicate a greater focus on quality improvements and thus may limit reproducibility at other hospitals.

Conclusion {#jah32576-sec-0019}
==========

A national STEMI regionalization program was associated with an increase in the proportions of male and white patients who are reperfused within guideline goals for FMC‐to‐device time that was not evident for female or black patients. These results highlight future opportunities to further narrow treatment differences among disparate populations.
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